Search Results 651-660 of 15663 for substance P

  1. Spinal cord tumor - Doctors and departments - Mayo Clinic

    Last Name Initial: P,P. Research. Spinal cord tumor research is conducted in coordination with Mayo Clinic Comprehensive Cancer Center. Mayo Clinic ...

  2. Pituitary tumors - Doctors and departments - Mayo Clinic

    Learn about our team of pituitary tumor doctors, surgeons and specialists who are researching new ways of diagnosing and treating this condition.

  3. Neuroendocrine tumors - Doctors and departments - Mayo Clinic

    Displaying 1-9 out of 9 doctors available. Last Name Initial: P ...

  4. Neuroendocrine tumors - Doctors and departments - Mayo Clinic

    Find a doctor whose last name begins with the letter P P; There are no doctors whose last name begins with the letter Q Q; Find a doctor whose last name ...

  5. Pneumonitis - Diagnosis and treatment - Mayo Clinic

    One option to help diagnose hypersensitivity pneumonitis is to avoid the suspected environmental substance for several weeks to see if symptoms get better.

  6. Peripheral artery disease (PAD) - Doctors and departments - Mayo Clinic

    This common blood flow condition can cause leg pain when walking. Lifestyle changes and medicines can help, but sometimes surgery is needed.

  7. Neuroendocrine tumors - Doctors and departments - Mayo Clinic

    Displaying 1-9 out of 9 doctors available. Last Name Initial: P ...

  8. Neuroendocrine tumors - Doctors and departments - Mayo Clinic

    Displaying 1-9 out of 9 doctors available. Last Name Initial: P ...

  9. Neuroendocrine tumors - Doctors and departments - Mayo Clinic

    Displaying 1-9 out of 9 doctors available. Last Name Initial: P ...

  10. A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 Positive, Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

    This study will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM. Participation eligibility.